273 related articles for article (PubMed ID: 31523835)
1. SLC1A3 contributes to L-asparaginase resistance in solid tumors.
Sun J; Nagel R; Zaal EA; Ugalde AP; Han R; Proost N; Song JY; Pataskar A; Burylo A; Fu H; Poelarends GJ; van de Ven M; van Tellingen O; Berkers CR; Agami R
EMBO J; 2019 Oct; 38(21):e102147. PubMed ID: 31523835
[TBL] [Abstract][Full Text] [Related]
2. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Chan WK; Horvath TD; Tan L; Link T; Harutyunyan KG; Pontikos MA; Anishkin A; Du D; Martin LA; Yin E; Rempe SB; Sukharev S; Konopleva M; Weinstein JN; Lorenzi PL
Mol Cancer Ther; 2019 Sep; 18(9):1587-1592. PubMed ID: 31209181
[TBL] [Abstract][Full Text] [Related]
3. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells.
Aslanian AM; Kilberg MS
Biochem J; 2001 Aug; 358(Pt 1):59-67. PubMed ID: 11485552
[TBL] [Abstract][Full Text] [Related]
4. Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.
Panosyan EH; Wang Y; Xia P; Lee WN; Pak Y; Laks DR; Lin HJ; Moore TB; Cloughesy TF; Kornblum HI; Lasky JL
Mol Cancer Res; 2014 May; 12(5):694-702. PubMed ID: 24505127
[TBL] [Abstract][Full Text] [Related]
5. A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
Sugimoto K; Suzuki HI; Fujimura T; Ono A; Kaga N; Isobe Y; Sasaki M; Taka H; Miyazono K; Komatsu N
Cancer Sci; 2015 Nov; 106(11):1534-43. PubMed ID: 26331698
[TBL] [Abstract][Full Text] [Related]
6. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines.
Su N; Pan YX; Zhou M; Harvey RC; Hunger SP; Kilberg MS
Pediatr Blood Cancer; 2008 Feb; 50(2):274-9. PubMed ID: 17514734
[TBL] [Abstract][Full Text] [Related]
7. Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells.
Aslanian AM; Fletcher BS; Kilberg MS
Biochem J; 2001 Jul; 357(Pt 1):321-8. PubMed ID: 11415466
[TBL] [Abstract][Full Text] [Related]
8. The inhibition of glutamine synthetase sensitizes human sarcoma cells to L-asparaginase.
Tardito S; Uggeri J; Bozzetti C; Bianchi MG; Rotoli BM; Franchi-Gazzola R; Gazzola GC; Gatti R; Bussolati O
Cancer Chemother Pharmacol; 2007 Oct; 60(5):751-8. PubMed ID: 17256128
[TBL] [Abstract][Full Text] [Related]
9. Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours.
Garcia-Bermudez J; Baudrier L; La K; Zhu XG; Fidelin J; Sviderskiy VO; Papagiannakopoulos T; Molina H; Snuderl M; Lewis CA; Possemato RL; Birsoy K
Nat Cell Biol; 2018 Jul; 20(7):775-781. PubMed ID: 29941933
[TBL] [Abstract][Full Text] [Related]
10. L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of β-catenin-mutated human hepatocellular carcinoma cells.
Tardito S; Chiu M; Uggeri J; Zerbini A; Da Ros F; Dall'Asta V; Missale G; Bussolati O
Curr Cancer Drug Targets; 2011 Oct; 11(8):929-43. PubMed ID: 21834755
[TBL] [Abstract][Full Text] [Related]
11. Asparaginase pharmacology: challenges still to be faced.
Lanvers-Kaminsky C
Cancer Chemother Pharmacol; 2017 Mar; 79(3):439-450. PubMed ID: 28197753
[TBL] [Abstract][Full Text] [Related]
12. A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3.
Tajan M; Hock AK; Blagih J; Robertson NA; Labuschagne CF; Kruiswijk F; Humpton TJ; Adams PD; Vousden KH
Cell Metab; 2018 Nov; 28(5):721-736.e6. PubMed ID: 30122553
[TBL] [Abstract][Full Text] [Related]
13. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).
Panosyan EH; Grigoryan RS; Avramis IA; Seibel NL; Gaynon PS; Siegel SE; Fingert HJ; Avramis VI
Anticancer Res; 2004; 24(2C):1121-5. PubMed ID: 15154634
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin B Is Not an Intrinsic Factor Related to Asparaginase Resistance of the Acute Lymphoblastic Leukemia REH Cell Line.
Costa IM; Effer B; Costa-Silva TA; Chen C; Ciccone MF; Pessoa A; Dos Santos CO; Monteiro G
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446393
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of glutamine synthetase triggers apoptosis in asparaginase-resistant cells.
Rotoli BM; Uggeri J; Dall'Asta V; Visigalli R; Barilli A; Gatti R; Orlandini G; Gazzola GC; Bussolati O
Cell Physiol Biochem; 2005; 15(6):281-92. PubMed ID: 16037693
[TBL] [Abstract][Full Text] [Related]
16. Expanding targets for a metabolic therapy of cancer: L-asparaginase.
Covini D; Tardito S; Bussolati O; Chiarelli LR; Pasquetto MV; Digilio R; Valentini G; Scotti C
Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):4-13. PubMed ID: 21854356
[TBL] [Abstract][Full Text] [Related]
17. Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines.
Chien WW; Le Beux C; Rachinel N; Julien M; Lacroix CE; Allas S; Sahakian P; Cornut-Thibaut A; Lionnard L; Kucharczak J; Aouacheria A; Abribat T; Salles G
Sci Rep; 2015 Jan; 5():8068. PubMed ID: 25626693
[TBL] [Abstract][Full Text] [Related]
18. Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities.
Majlessipour F; Kwock R; Martin-Aragon S; Weinberg KI; Avramis VI
Anticancer Res; 2001; 21(1A):11-22. PubMed ID: 11299723
[TBL] [Abstract][Full Text] [Related]
19. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia.
Bushman JE; Palmieri D; Whinna HC; Church FC
Leuk Res; 2000 Jul; 24(7):559-65. PubMed ID: 10867129
[TBL] [Abstract][Full Text] [Related]
20. Isolation, Purification, Characterisation and Application of L-ASNase: A Review.
Paul T; Mondal A; Bandyopadhyay TK
Recent Pat Biotechnol; 2019; 13(1):33-44. PubMed ID: 30318009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
